FOLH1 and neoplasm: The PRESTO—GETUG 36 study (NCT04115007) evaluates the efficacy of stereotaxic RT administered on all macroscopic tumour sites (up to 5 metastatic sites diagnosed by PSMA or FCH PET/CT or whole-body MRI) associated with reference treatment in patients with hormone-sensitive CP.